Albert Kwok

Let’s talk about the GOAT Albert Kwok, this guy is straight-up the real deal in biotech. Dude’s a YC W21 alum, so he’s been around the block and knows how to hustle. Started out grinding in biotech labs, got his PhD in Molecular Medicine, then kept climbing, masters in Biomedicine, bachelor’s in biotech. Basically, he’s been deep in the science game forever.

Before he co-founded Nuntius Therapeutics, he was a Senior Research Scientist at MiNA. That’s where he really got into modern stuff like mRNA delivery tech and machine learning-guided discovery. Think about it, he’s combining biotech with AI to crack the code on targeting tissues with genetic medicines. That’s advanced, holy shit stuff.

In 2021, he jumped into the startup world, co-founding Nuntius in London, a company backed by YC, so they’re serious. The mission? Developing cell-specific genetic medicines to tackle diseases that are currently incurable. They’re trying to solve the big problem in gene therapy, delivery. How do you get DNA, RNA, or CRISPR exactly where it needs to go without messing everything up? Albert and his team are innovating hard here, using machine learning to find the best carriers for tissue targeting. Basically, he’s pushing the envelope on how we can cure rare diseases with precision medicine.

What’s crazy is, this guy’s not just stuck in the lab. He’s out there, crushing it in the European biotech scene, speaking at summits, sharing knowledge, and really pushing the whole industry forward. He’s all about having an effect beyond his startup; he cares about lifting the community as a whole.

So, what does this all say about Albert? He’s a scientist turned founder who’s obsessed with solving big problems, not just for the sake of science but to actually change lives. He’s the perfect blend of deep tech expertise and entrepreneurial hustle. His process screams passion for breakthroughs and a relentless drive to turn complex science into real, usable medicines. Basically, he’s the guy who’s gonna crack some of the hardest biotech problems out there. No Cap, he’s the real deal, and he’s just getting started.